Role of vitamin D supplementation in chronic urticaria patients
Phase 3
- Conditions
- Health Condition 1: - Health Condition 2: L509- Urticaria, unspecified
- Registration Number
- CTRI/2023/08/056420
- Lead Sponsor
- Dr Disha Chakraborty
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient of chronic spontaneous urticaria presenting in the outpatient department of
Dermatology.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. There can be altered levels of serum vitamin D in the patients of CSU when <br/ ><br>compared to age-matched healthy control at baseline. <br/ ><br>2. There can be correlations of serum vitamin D levels with disease severity & duration at baseline, 4 weeks, 8 weeks. <br/ ><br>3. There can be a difference in disease control (UAS7 score and) tablet score between the two groups at baseline, 4 weeks and the end of 8 weeks. <br/ ><br>Timepoint: 1. There can be altered levels of serum vitamin D in the patients of CSU when <br/ ><br>compared to age-matched healthy control at baseline. <br/ ><br>2. There can be correlations of serum vitamin D levels with disease severity & duration at baseline, 4 weeks, 8 weeks. <br/ ><br>3. There can be a difference in disease control (UAS7 score and) tablet score between the two groups at baseline, 4 weeks and the end of 8 weeks. <br/ ><br>
- Secondary Outcome Measures
Name Time Method Is there any correlations of serum vitamin D levels with disease severity & duration. <br/ ><br>Is there can be a difference in disease control (UAS7 score and) tablet score between the two groups at the end of 8 weeks? <br/ ><br>Timepoint: 8 weeks